UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

The lancet oncology, 2018-06, Vol.19 (6), p.737-746

2018

Volltextzugriff (PDF)

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

The Lancet (British edition), 2017-03, Vol.389 (10075), p.1195-1205

2017

Volltextzugriff (PDF)

Challenges of Guarantee-Time Bias

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2963-2969

2013

Volltextzugriff (PDF)

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2019-08, Vol.111 (8), p.772-781

2019

Volltextzugriff (PDF)

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

Journal of clinical oncology, 2016-03, Vol.34 (9), p.927-935

2016

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

The New England journal of medicine, 2017-07, Vol.377 (2), p.122-131

2017

Volltextzugriff (PDF)

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

BMJ (Online), 2021-12, Vol.375, p.e066381

2021

Volltextzugriff (PDF)

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Journal of clinical oncology, 2016-04, Vol.34 (10), p.1034-1042

2016

Volltextzugriff (PDF)

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Journal of clinical oncology, 2013-09, Vol.31 (25), p.3083-3090

2013

Volltextzugriff (PDF)

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

The lancet oncology, 2014-09, Vol.15 (10), p.1137-1146

2014

Volltextzugriff (PDF)

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

The lancet oncology, 2014-02, Vol.15 (2), p.156-163

2014

Volltextzugriff (PDF)

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

The New England journal of medicine, 2015-03, Vol.372 (10), p.923-932

2015

Volltextzugriff (PDF)

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Journal of clinical oncology, 2021-05, Vol.39 (13), p.1448-1457

2021

Volltextzugriff (PDF)

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Journal of clinical oncology, 2020-04, Vol.38 (12), p.1293-1303

2020

Volltextzugriff (PDF)

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Journal of clinical oncology, 2014-07, Vol.32 (20), p.2159-2165

2014

Volltextzugriff (PDF)

Sex and cancer immunotherapy: Current understanding and challenges

Cancer cell, 2022-07, Vol.40 (7), p.695-700

2022

Volltextzugriff (PDF)

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Clinical cancer research, 2021-08, Vol.27 (15), p.4311-4324

2021

Volltextzugriff (PDF)

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

Journal of clinical oncology, 2008-08, Vol.26 (24), p.3913-3915

2008

Volltextzugriff (PDF)

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

Journal of clinical oncology, 2017-04, Vol.35 (11), p.1179-1188

2017

Volltextzugriff (PDF)

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2452-2459

2016

Volltextzugriff (PDF)

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

The lancet oncology, 2011-11, Vol.12 (12), p.1101-1108

2011

Volltextzugriff (PDF)

1 – 25 von 677

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(660)
Mit Volltextzugriff
(484)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(471)
Science & Technology
(400)
Female
(392)
Life Sciences & Biomedicine
(392)
Oncology
(276)
Breast Cancer
(237)
Breast Neoplasms - Drug Therapy
(232)
Medical Sciences
(165)
Biological And Medical Sciences
(164)
Middle Aged
(140)
Chemotherapy, Adjuvant
(133)
Breast Neoplasms - Pathology
(132)
Adult
(119)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(118)
Chemotherapy
(114)
Tumors
(105)
Breast Neoplasms - Surgery
(97)
Aged
(96)
Treatment Outcome
(90)
Disease-Free Survival
(89)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Challenges of Guarantee-Time Bias

Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis

Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

Patterns of Recurrence and Outcome According to Breast Cancer Subtypes in Lymph Node–Negative Disease: Results From International Breast Cancer Study Group Trials VIII and IX

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response

Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial

Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)

Sex and cancer immunotherapy: Current understanding and challenges

Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study

Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

Aktive Filter

Suchergebnisse filtern